Navigation Links
EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital
Date:6/1/2011

COLUMBUS, Ohio, June 1, 2011 /PRNewswire/ -- EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of a highly oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm.  EndoSphere Inc., which holds 23 U.S. and international issued and pending patents, will use the funding to expand its intellectual property assets and to complete additional clinical product testing.

"EndoSphere is extremely fortunate to align itself with Broadline Capital, which offers a rare blend of global financial expertise and pragmatic operating experience," said James McKinley, EndoSphere CEO.

Broadline Capital was formed in 2005 by Christopher Thorne, an early pioneer in China's private equity industry and former management consultant at McKinsey & Company.  Thorne previously founded and developed a software technology company that created efficiency gains for manufacturers, distributors and retailers in the trillion-dollar food and beverage, consumer packaged goods and retail supply chains.  The resulting company sold to institutional investors at a nine-figure enterprise valuation in 2007.

"An investment in EndoSphere presented us with a unique opportunity to invest in, and support, an exciting portfolio of intellectual property assets and a highly experienced management team," said Thorne. "EndoSphere's technology brings an innovative approach to treating obesity, which has become one of the largest health problems worldwide."

The company is planning a multi-center clinical trial while continuing its research and development of innovative and profitable applications.  

"With the support of this financing, EndoSphere is poised to fulfill the potential of the technology and the expectations of the investors,"
'/>"/>

SOURCE EndoSphere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... According to a recent report from ... chronic back pain, TMJ disorders are the second ... disability. In addition, the report revealed that TMJ disorders ... costing an estimated 4 billion dollars annually. , These ... seemingly unrelated symptoms such as headaches, neck pain, tenderness ...
(Date:4/27/2015)... Thanks to a $7.5 million grant from ... institutions, including American University, will operate in a new ... behavioral research aimed at ending the AIDS epidemic. , ... HIV or AIDS, according to the latest statistics. At ... over the age of 13 was living with HIV, ...
(Date:4/27/2015)... April 27, 2015 Doctors on Liens ... on a lien basis for over twenty years. So when ... the best doctor in the Fresno area , Doctors ... DC and his team of medical specialists. With a ... massage therapist, Dilanchian Chiropractic is now helping more ...
(Date:4/27/2015)... Church, VA (PRWEB) April 27, 2015 ... Integrity Issues Within Your Operations or Your Partners/Suppliers, **FDAnews ... p.m. EDT, http://www.fdanews.com/DataIntegrity , Data integrity issues ... the last few years., Uncovering data integrity issues within ... once data integrity issues come to light, remediating them ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 FMC Corporation’s ... exhibit its wide range of market leading ingredients and ... 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects to ... countries showcasing the latest research in such areas as ... , FMC Health and Nutrition’s booth will feature ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... ... some people have questioned if the HCG diet can be harmful. Dr Robert True addresses ... , ... Dr. Robert sees patients on a daily basis that he helps lose weight through his ...
... ... BtoB companies seeking a proven approach for lead cultivation with social media. , ... Portland, OR (PRWEB) March 24, 2010 -- ... Five Ways to Leads: How BtoBs Should Use Social Media , a complimentary Webinar event ...
... This release is available in Spanish . ... same area as the original tumour remains the strongest, independent ... who have been free of disease for a very long ... European Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, ...
... available in Spanish . Barcelona, Spain: ... goal in survival with new treatment should be to prolong ... might expect from using current best therapies, a researcher will ... today (Wednesday). This finding contrasts with doctors, perception that an ...
... the Barcelona Public Health Agency has revealed those sections of ... published in the journal Respiratory Research , shows that ... aged over 50 or infected with HIV. "Some patients ... of six months), resulting in a danger of them infecting ...
... the death of a loved one can provide much-needed consolation ... study in the April issue of the Journal of ... a relative to cancer took part in the study. Participants ... widows, widowers, daughters and sisters. Nine chose foot massage, eight ...
Cached Medicine News:Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Webinar Shares Proven Social Media Approach to BtoB Lead Generation 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older people and those with HIV are more vulnerable to tuberculosis 2Health News:Hand and feet massages provide consolation for bereaved relatives 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: